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Introduction 1
Tea is the most commonly consumed drink in the world after water. Depending on 2 the manufacturing process, tea can be classified into three major classes: non-3 fermented green tea, semi-fermented oolong tea and fermented black and red teas 4 (Cabrera et al., 2006) . Non-fermented green tea from the plant Camellia sinensis is 5 dried and steamed to prevent oxidation which is not the case for black and red tea 6 (Cabrera et al., 2006) . The natural compound epigallocatechin-3-gallate (EGCG) is 7 an active polyphenolic catechin and accounts for approximately 59% of the total 8
catechins from the leaves of the green tea. Other catechins in green tea include 9 epigallocatechin (EGC) (19%), epicatechin-gallate (ECG) (13.6%) and epicatechin 10 (EC) (6.4%) (McKay and Blumberg, 2002) . The functional and structural differences 11 of these catechins are attributed to the number of hydroxyl groups on the B-ring and 12 the presence or absence of a galloyl moiety ( Figure 1) . 13 In traditional Chinese medicine, green tea has been considered to have beneficial 14 properties for human health including cardioprotective, anti-carcinogenetic and anti-15 infective effects. Although a detailed molecular understanding why green tea has 16 these broad protective effects is lacking, the ability of EGCG to bind many biological 17 molecules and influence a variety of enzymes activities and signal transduction 18 pathways at micromolar and nanomolar levels may at least in part be responsible 19 (Lee et al., 2002) . EGCG is water soluble and high temperature exposure like boiling 20 water does not greatly influence the stability of the molecule . 21 Notably, EGCG and various green tea preparations are available as an over the 22 counter remedy in many countries and are inexpensive. The first documented report 23
of an anti-infective activity of tea was made over 100 years ago by the British army 24 high-affinity binding of EGCG to the CD4 molecule with a K d of approximately 10 1 nmol/L (Williamson et al., 2006) . Physiologically relevant concentration of EGCG (0.2 2 µmol/L) inhibited binding of gp120 to isolated human CD4 T cells. Molecular 3 modeling studies suggested a binding site for EGCG in the D1 domain of CD4, the 4 pocket that gp120 binds (Williamson et al., 2006) . The HIV-1 integrase protein is 5 responsible for the insertion of HIV proviral DNA into the genome of infected cells. 6
Recently, EGCG was also evaluated for the ability to inhibit the HIV-1 integrase in an 7
ELISA assay (Jiang et al., 2010) . It was shown that catechins with a galloyl moiety 8 were able to reduce HIV-1 integration by binding between the integrase and the viral 9 DNA disrupting this interaction. However, further studies validating these in vitro 10 experiments with infectious viruses should be performed. 11
In conclusion, EGCG appears to interfere with multiple aspects of the HIV-1 life-12 cycle, including virion destruction via interaction with the viral envelope, abrogation 13 of viral replication via inhibition of reverse transcription, inhibition of proviral genome 14 integration and CD4 receptor downregulation. Most conclusively, competition with 15 gp120 for CD4 binding was validated in several independent studies. Importantly, 16 physiological EGCG concentrations were able to reduce the attachment of gp120 to 17 CD4 by a factor of 20-fold and further studies in vivo are required to judge if EGCG 18 has promise as a potential future antiretroviral therapy. 19 
20

Effect of EGCG on other viruses 21
With respect to RNA viruses, EGCG was tested against two other viruses, 22 enterovirus 71 belonging to the family of Picornaviridae and influenza viruses which who tested the structure-activity relationship of the different green tea polyphenolic 22 compounds EGCG, ECG and EGC against influenza (Song et al., 2005) . They found 23 that ECG and EGCG were more effective than EGC and the molecules also exerted 24 an inhibitory effect on the neuraminidase in a biochemical assay. Influenza viral RNA 25 et al., 2005) . Interestingly, based on these in vitro data clinical studies were 1 performed to investigate if green tea catechins can prevent influenza infections in 2 humans. In a small prospective cohort study it was reported that gargling with tea 3 catechins extracts was effective in preventing influenza infection in elderly nursing 4 home residents (Yamada et al., 2006) . In addition, another randomized, double-5 blind, placebo-controlled trial consuming catechins for 5 months had a statistically 6 significant preventive effect on clinically defined influenza infection and was well 7 tolerated (Matsumoto et al., 2012). These trails raise hope for the protective effect of 8 catechins against influenza virus, however, large-scale studies are needed to 9 confirm this effectiveness. and -in some cases -acute liver failure. Chronic hepatitis B that affects over 300 1 million HBV persists even after clinical resolution of acute infection and can be 2 reactivated causing severe disease under conditions of immunosuppression. In 3 contrast to HCV, a preventive vaccine for HBV and specific antiviral drugs are 4 available. However, viral resistance increasingly poses a challenge (Tillmann, 2007) . 5
To elucidate the effect of green tea catechins against HBV, green tea extracts and 6 EGCG were studied in the stable cell line HepG2-N10 expressing HBV antigens (Xu 7 et al., 2008) . The authors observed that expression of HBV specific antigens, the 8 levels of extracellular HBV DNA, intracellular replicative intermediates and cccDNA 9
were reduced in a dose-dependent manner (Xu et al., 2008) . However, it is difficult to 10 dissect the detailed anti-HBV mechanisms of EGCG using HepG2-N10 cells as the 11 process from cccDNA to antigen expression are strongly affected by transcription of In case of other DNA viruses, EGCG has been analyzed so far against adenovirus, 23
Epstein-Barr virus (EBV) and Herpes simplex virus (HSV-1), the two latter one 24 belonging to the family of Herpesviridae. Adenoviruses are non-enveloped viruses 25 57 described serotypes in humans, which are responsible for 5-10% of upper 1 respiratory infections in children. Humans infected with adenoviruses display a wide 2 range of responses, from no symptoms at all to the severe infections typical of 3 adenovirus serotype 14. When the antiviral effect of green tea was studied on 4 adenovirus infection, the virus yield could be reduced by two orders of magnitude in 5
Hep2 cells (Weber et al., 2003) . The molecule was most effective when added to the 6 cells during the transition from early to late phase of viral infection suggesting EGCG 7 inhibits one or more late steps in virus infection (Weber et al., 2003) . Furthermore, 8 inactivation of purified adenoviruses and inhibition of viral protease activity was 9 noted. The therapeutic value, however, seem to be limited as the effective 10 concentrations were high above the reported serum concentration of green tea 11 drinkers. This was also the case when EGCG was tested against EBV. EBV is a 12 human herpesvirus causing infectious mononucleosis and is closely associated with 13
Burkitt's lymphoma, nasopharyngeal carcinoma, T-cell lymphoma and Hodgkin's 14 disease (Bravender, 2010) . show those purified viruses exposed to EGCG were damaged. As EGCG is stable 6 on the pH range found in the vagina it was proposed that the green tea molecule 7 could be a promising candidate for use in a microbiocide to reduce HSV The mechanism of action of EGCG against staphylococci was further investigated by 13
Yam and co-workers who demonstrated that tea extracts can reverse the phenotypic 14 methicillin resistance in MRSA (Yam et al., 1998) . Tea extracts at 25 µg/mL were 15 able to inhibit the production of PBP2 by >90% in a constitutively PBP2 producing S. 16 aureus strain. In addition, the production of beta-lactamases was inhibited. In 17 contrast to the study from Yam et al., suppression of PBP2 could not be detected by 18
Zhao et al. either by PBP2 mRNA expression using quantitative PCR or by PBP2 19 production using latex agglutination (Zhao et al., 2002) . 20
Combination testing of tea extracts and beta-lactams (methicillin, benzylpenicillin) 21 mostly demonstrated a synergistic antibacterial effect. These results were mainly 22 confirmed by Zhao and colleagues who showed that 25 µg/mL EGCG was able to 23 reverse the high level resistance of MRSA to all types of beta-lactams, including 24 benzylpenicillin, oxacillin, methicillin, ampicillin and cephalexin (Zhao et al., 2001b ). al., 2002). As previously reported, also the production of penicillinase from penicillin-7 resistant S. aureus was inhibited by EGCG in a dose-dependent manner. 8
Besides EGCG, ECG was also able to reverse beta-lactam resistance in clinical 9
MRSA isolates (Stapleton et al., 2004) . It was shown that the gallate moiety of EGC 10 was essential for oxacillin-modulating activity, as both (-)-epicatechin and (-)-11 epicatechin-3-cyclohexylcarboxylate were unable to reverse resistance. 12
Results from Shimamura and co-workers indicated that EGCG binds directly or In experiments using BALB/c mice and human PBMCs, polyphenon, consisting of 11 50% EGCG, could neutralize staphylococcal enterotoxin B in a dose-and incubation For that reason it was hypothesized that the physiological function of the outer 10 membrane and low affinity of the also negatively charged EGCG to the bacterial cell 11 membrane reduce the antibacterial activity of EGCG against gram-negative bacteria 12
(Yoda et al., 2004). 13
The gram-negative non-fermentative bacillus Stenotrophomonas maltophilia is 14 intrinsically resistant to beta-lactams and other broad-spectrum antibiotics and has 15 emerged globally as an important nosocomial pathogen (Brooke, 2012 EGCG against bacteria causing food-borne disease is shown in Table 2 . 
EGCG against fungi 22
Over 600 different fungi have been reported to infect humans, ranging from common 23 to fatal infections (Brown et al., 2012) . They infect billions of people every year and 24 due to the more modern and interventional medicine and the increase ofantifungal effects of EGCG were mainly studied against yeasts such as Candida spp. 1 and molds such as dermatophytes. Currently, data concerning aspergilli or other 2 human-pathogenic fungi as zygomycetes are lacking. The dermatophytes are a distinct group of fungi which have the ability to utilize 10 keratin as a nutrition source. These fungi cause superficial infections of the skin, hair 11 and nails of humans and animals. 12
The problem with the most currently available antifungals is not the existing 13 antimycotic activity; it is more the potential side effects of the different classes of 14 drugs as most of them are nephro-or hepatotoxic. Thus, developing and testing 15 compounds from nature with less toxic effects is desirable. However, the tea extract with EGCG inhibited the growth of Trichphyton in a dose-21 and contact time-dependent manner. Using scanning and transmission electron 22 microscopy to study the mode of action, the same research group examined the 23 effects of EGCG against T. mentagrophytes (Toyoshima et al., 1994) . EGCG was 24
shown to inhibit the germination of conidia and subsequent hyphal growth. After 25 in terms of deformation and swelling and after five days most of the ungerminated 1 conidia were broken down. In addition, the hyphal cell walls were exfoliated. It was 2 concluded that EGCG can cause lysis of the conidia and hyphae suggesting an 3 antidermatophytic effect against T. mentagrophytes. 4
It took over 15 years before the next study investigated the in vitro activity of EGCG 5 against clinical isolates of dermatophytes (Park et al., 2011) . The susceptibility of 35 6 dermatophytes was tested against wide range of EGCG concentrations using the 7 standard protocol (M38-A2) from the Clinical and Laboratory Standards Institute 8 (CLSI). The MIC 50 and MIC 90 of EGCG were 2-4 µg/mL and 4-8 µg/mL, respectively. 9
Interestingly, T. rubrum was more susceptible than T. mentagrophytes and 10
Microsporum canis. It was suggested to perform in vivo or ex vivo experiments to 11 verify a potential effect of EGCG. The results from another investigation evaluating the antifungal activity of EGCG 24 (CLSI M27-A) on 21 clinical isolates of seven Candida species in vitro was mainly in 25 EGCG against C. albicans was >16 µg/mL whereas C. glabrata, C. guilliemondii and 1 C. parapsilosis exhibited the highest susceptibility (MIC 90 ; 1-16 µg/mL). As expected, 2 most antifungals revealed lower MIC values against Candida spp. than EGCG. It 3 was suggested to use EGCG as possible agent or adjuvant for antifungal therapy in 4 candidiasis. However, the mechanism of antifungal effect has not been defined and 5
in vivo experiments are currently lacking. 6
Indeed a limitation of these studies is the fact that only in vitro testing of EGCG was 7 performed. Besides in vitro testing, another important issue is studying the 8 underlying mechanisms of action of EGCG. Furthermore, it would be desirable to 9
confirm the in vitro test results in in vivo experiments. Up to now, three studies tried 10 to address these issues: 11
In an in vitro study, it was shown that EGCG, EGC and ECG causes metabolic 12 instability to C. albicans cultures even at physiological polyphenol concentrations 13 In summary, most data concerning the antifungal in vitro and in vivo activity of EGCG 22 exists against Candida indicating that EGCG can be an additional or alternative 23 therapeutic agent against disseminated candidiasis. However, future work is needed 24 to determine the in vivo efficiency in different settings and dosages of EGCG. 25
Conclusions 1
In this review, the anti-infective effects of EGCG against viruses, bacteria and 2 different fungi were summarized and discussed. A comparison of the antiviral activity 3 of EGCG (Table 1) kinetics of EGCG were assessed at intervals for a time frame of 26 hours after 6 administration. The mean total EGCG area under the concentration-time curve from 7 0 h to infinity AUC (0-∞) ranged from 442 to 10,368 ng h/ml and the mean terminal 8 elimination half-life t 1/2z were seen from 1.9 to 4.6 h. Importantly, doses of purified 9 EGCG up to 1600 mg were generally well tolerated (Ullmann et al., 2003) . 10
In addition, recent attempts have been made trying to enhance the activity of EGCG. 11
For example, the bioavailability of EGCG can be increased by chronic 800 mg 12 
